Mutual of America Capital Management LLC Sells 1,180 Shares of Haemonetics Co. (NYSE:HAE)

Mutual of America Capital Management LLC lessened its stake in shares of Haemonetics Co. (NYSE:HAE) by 3.9% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,079 shares of the medical instruments supplier’s stock after selling 1,180 shares during the period. Mutual of America Capital Management LLC’s holdings in Haemonetics were worth $2,406,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. TFO Wealth Partners LLC increased its position in Haemonetics by 29,450.0% during the 4th quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier’s stock valued at $51,000 after buying an additional 589 shares in the last quarter. Covestor Ltd increased its holdings in shares of Haemonetics by 184.8% in the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after purchasing an additional 438 shares in the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Haemonetics in the 2nd quarter worth $82,000. EntryPoint Capital LLC bought a new stake in shares of Haemonetics in the 1st quarter worth $86,000. Finally, Headlands Technologies LLC bought a new stake in shares of Haemonetics in the 1st quarter worth $114,000. Institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on HAE. Bank of America began coverage on Haemonetics in a report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 target price for the company. Citigroup reduced their target price on Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday, August 22nd. BTIG Research assumed coverage on Haemonetics in a report on Tuesday, September 10th. They issued a “buy” rating and a $112.00 price objective for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $125.00 price objective on shares of Haemonetics in a report on Tuesday, August 13th. Finally, Needham & Company LLC raised Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price objective for the company in a report on Wednesday, June 12th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $106.14.

Haemonetics Trading Down 1.2 %

HAE opened at $75.50 on Wednesday. The stock has a market cap of $3.85 billion, a price-to-earnings ratio of 32.97, a P/E/G ratio of 1.32 and a beta of 0.30. The stock’s 50 day moving average price is $79.62 and its 200-day moving average price is $84.01. Haemonetics Co. has a one year low of $70.74 and a one year high of $97.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.33 and a current ratio of 3.76.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.03 by ($0.01). Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The firm had revenue of $336.17 million during the quarter, compared to the consensus estimate of $335.08 million. During the same period last year, the company earned $1.05 EPS. The firm’s revenue for the quarter was up 8.0% compared to the same quarter last year. On average, equities analysts forecast that Haemonetics Co. will post 4.58 EPS for the current year.

Insider Buying and Selling at Haemonetics

In other Haemonetics news, EVP Anila Lingamneni sold 2,136 shares of the stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total transaction of $192,240.00. Following the sale, the executive vice president now owns 21,410 shares of the company’s stock, valued at approximately $1,926,900. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Haemonetics news, EVP Anila Lingamneni sold 2,136 shares of the stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total transaction of $192,240.00. Following the sale, the executive vice president now owns 21,410 shares of the company’s stock, valued at approximately $1,926,900. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Stewart W. Strong sold 4,312 shares of the stock in a transaction on Friday, July 26th. The shares were sold at an average price of $91.15, for a total value of $393,038.80. Following the sale, the insider now owns 18,196 shares of the company’s stock, valued at approximately $1,658,565.40. The disclosure for this sale can be found here. Insiders own 1.80% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.